Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022 - 2024)

Coherus Oncology's Long-Term Debt Repayments history spans 2 years, with the latest figure at $85.4 million for Q2 2024.

  • For Q2 2024, Long-Term Debt Repayments changed N/A year-over-year to $85.4 million; the TTM value through Sep 2025 reached $85.4 million, down 24.19%, while the annual FY2025 figure was $233.2 million, 10.45% down from the prior year.
  • Long-Term Debt Repayments for Q2 2024 was $85.4 million at Coherus Oncology, up from $27.2 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $111.1 million in Q1 2022 and bottomed at -$29.4 million in Q2 2022.